Should residents’ access to Alzheimer’s drug be restricted?
By
Lois A. Bowers
Jan 18, 2022
You have until Feb. 10 to share your comments with CMS about its recent proposal related to Alzheimer’s drug aducanumab (Aduhelm).
A very troubling $56 billion question
By
John O'Connor
Jul 08, 2021
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.
GAO has good points in how, why antipsychotics are given
By
Elizabeth Newman
Mar 04, 2015
The government recognizes the progress made in nursing homes with reduction of antipsychotics for residents with dementia, but also notes many who live in assisted living are receiving the drugs. It’s...